Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy.

Beteiligte Wissenschaftler:
Univ.-Prof. Dr. rer. nat. et med. habil. Andreas Faldum
Prof. Dr. René Schmidt

Kooperationspartner:
Univ.-Prof. Dr. O. Witt, Deutsches Krebsforschungszentrum (DKFZ)